Back
Framework for Nucleic Acid Synthesis Screening
governmentbidenwhitehouse.archives.gov·bidenwhitehouse.archives.gov/ostp/news-updates/2024/04/29...
Relevant to AI safety discussions around dual-use technology governance; this framework models how governments can establish screening and safeguards for powerful biotechnologies, offering lessons for analogous AI governance challenges.
Metadata
Importance: 62/100guidance documentprimary source
Summary
The Biden White House Office of Science and Technology Policy (OSTP) released a framework establishing standards for screening nucleic acid synthesis orders to prevent misuse for biological weapons or pandemic-causing agents. The framework aims to create consistent biosecurity screening protocols across the DNA/RNA synthesis industry. It represents a key policy intervention at the intersection of biotechnology capabilities and biosecurity governance.
Key Points
- •Establishes baseline screening requirements for providers of synthetic nucleic acids to detect and prevent orders for dangerous biological sequences.
- •Addresses the dual-use risk that commercial DNA/RNA synthesis services could be exploited to create pathogens or toxins with pandemic potential.
- •Calls for both sequence screening (checking against dangerous pathogen databases) and customer screening to verify legitimate use.
- •Part of broader Biden administration biosecurity efforts alongside the Executive Order on AI and the National Biosurveillance Strategy.
- •Creates voluntary but strongly encouraged industry standards, with potential to evolve into regulatory requirements over time.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Bioweapons Risk | Risk | 91.0 |
Cached Content Preview
HTTP 200Fetched Mar 15, 20264 KB
Framework for Nucleic Acid Synthesis Screening | OSTP | The White House
Skip to content
This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.
Today, as directed by President Biden’s Executive Order on the Safe, Secure, and Trustworthy Development of Artificial Intelligence (AI), the White House Office of Science and Technology Policy (OSTP) is releasing a Framework on Nucleic Acid Synthesis Screening to encourage providers of synthetic nucleic acids to implement comprehensive, scalable, and verifiable screening mechanisms. This framework helps manage the risks of AI so that we can seize its benefits in synthetic biology.
Through the AI executive order, President Biden has directed action on AI across the economy, including AI applied to biotechnology and synthetic biology. Nucleic acids serve as the critical building blocks for life science research and development (R&D) —including the development of new biomedical products, novel strategies for recycling and energy production, and the creation of new classes of materials. It is essential that nucleic acid synthesis technologies are appropriately managed to promote positive outcomes and prevent nefarious uses. Nucleic acid synthesis screening is an effective, targeted measure to mitigate the potential for misuse of AI-enabled biotechnologies.
This framework recommends that providers of synthetic nucleic acids screen purchases to prevent misuse, building on recent guidance from the Department of Health and Human Services. The National Institute of Standards and Technology will further support implementation of this framework by engaging with industry to develop technical standards for screening, as directed by the Executive Order.
As directed by the Executive Order, within 180 days of the release of this framework, federal research funding agencies will require recipients of federal R&D funds to procure synthetic nucleic acids only from providers that implement these best practices. While this framework establishes requirements for federally funded research, it is anticipated that these requirements may be adopted more broadly by other research funders.
The Framework for Nucleic Acid Synthesis Screening can be found here .
OSTP is making the following email address available to collect feedback from stakeholders on interpreting and/or implementing this policy. Feedback will be used for policy evaluation purposes and may result in FAQs. Not all emails will receive a response.
###
Editors Note – September 2024 Revisions Include:
Clarification that Providers may still be adherent to the Framework if they identify “exempted sequences” that qualify as SOCs but pose no known pathogenic or toxicity risk. Providers are not required to verify customer legitimacy fo
... (truncated, 4 KB total)Resource ID:
14ff22ab7e571166 | Stable ID: ZTU2ZDQ0NW